Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales

Rhythm Pharmaceuticals

04/11/2025 12:09

Overview

Rhythm Q3 2025 product revenue rises 54% yr/yr, driven by IMCIVREE sales

Net income for Q3 2025 misses analyst expectations, larger loss reported

FDA accepts sNDA for setmelanotide in acquired hypothalamic obesity, decision by Dec 20

Outlook

Company expects FDA decision on sNDA by December 20, 2025

Rhythm anticipates Q4 2025 results from Phase 2 trial in Prader-Willi syndrome

Company updates 2025 Non-GAAP Operating Expenses guidance to $295 mln-$315 mln

Result Drivers

U.S. SALES GROWTH - Revenue from U.S. sales increased 19% sequentially, driven by growth in IMCIVREE sales for BBS

INTERNATIONAL SALES DECLINE - Revenue outside the U.S. decreased 21% sequentially due to ordering variability and a one-time pricing adjustment in France

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Product Revenue
$51.29 mln
Q3 Net Income
Miss
-$52.90 mln
-$45.50 mln (11 Analysts)
Q3 Basic EPS
-$0.82
Q3 Operating Income
-$52.65 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $121.50, about 6.4% above its November 3 closing price of $113.74

Press Release: ID:nGNX9dXFQH

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)